Evoke Pharma, Inc. (EVOK) financial statements (2021 and earlier)

Company profile

Business Address 420 STEVENS AVENUE
SOLANA BEACH, CA 92075
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments8684677
Cash and cash equivalents8684677
Receivables0      
Inventory, net of allowances, customer advances and progress billings00     
Inventory00     
Prepaid expense1000110
Other current assets0000 00
Total current assets:9785678
Noncurrent Assets
Operating lease, right-of-use asset000000 
Other noncurrent assets0   0  
Other undisclosed noncurrent assets      0
Total noncurrent assets:0000000
TOTAL ASSETS:9785678
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:1111110
Employee-related liabilities1111111
Other undisclosed accounts payable and accrued liabilities00(0)000(0)
Debt  0000 
Other undisclosed current liabilities6661111
Total current liabilities:8772221
Noncurrent Liabilities
Long-term debt and lease obligation522    
Long-term debt, excluding current maturities522    
Liabilities, other than long-term debt00     
Accounts payable and accrued liabilities00     
Total noncurrent liabilities:522    
Total liabilities:13992221
Stockholders' equity
Stockholders' equity attributable to parent(3)(2)(0)3456
Common stock0000000
Additional paid in capital96959490908989
Accumulated deficit(99)(97)(94)(88)(86)(84)(83)
Total stockholders' equity:(3)(2)(0)3456
TOTAL LIABILITIES AND EQUITY:9785678

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Revenues0      
Operating expenses(2)(2)(7)(2)(1)(2)(2)
Other undisclosed operating income0      
Operating loss:(2)(2)(7)(2)(1)(2)(2)
Nonoperating income (expense)(0)(0)(0)0000
Interest and debt expense(0)(0)(0)    
Net loss:(2)(2)(7)(2)(1)(2)(2)
Other undisclosed net income attributable to parent000    
Net loss available to common stockholders, diluted:(2)(2)(7)(2)(1)(2)(2)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net loss:(2)(2)(7)(2)(1)(2)(2)
Comprehensive loss, net of tax, attributable to parent:(2)(2)(7)(2)(1)(2)(2)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: